Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer
Standard
Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer. / Höflmayer, Doris; Fraune, Christoph; Hube-Magg, Claudia; Simon, Ronald; Schroeder, Cornelia; Büscheck, Franziska; Möller, Katharina; Dum, David; Weidemann, Sören; Wittmer, Corinna; Schlomm, Thorsten; Huland, Hartwig; Heinzer, Hans; Graefen, Markus; Haese, Alexander; Sauter, Guido; Burandt, Eike; Clauditz, Till S; Steurer, Stefan; Minner, Sarah; Wilczak, Waldemar; Polonski, Adam.
In: APPL IMMUNOHISTO M M, Vol. 29, No. 4, 01.04.2021, p. e29-e38.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Overexpression of the TRIM24 E3 Ubiquitin Ligase is Linked to Genetic Instability and Predicts Unfavorable Prognosis in Prostate Cancer
AU - Höflmayer, Doris
AU - Fraune, Christoph
AU - Hube-Magg, Claudia
AU - Simon, Ronald
AU - Schroeder, Cornelia
AU - Büscheck, Franziska
AU - Möller, Katharina
AU - Dum, David
AU - Weidemann, Sören
AU - Wittmer, Corinna
AU - Schlomm, Thorsten
AU - Huland, Hartwig
AU - Heinzer, Hans
AU - Graefen, Markus
AU - Haese, Alexander
AU - Sauter, Guido
AU - Burandt, Eike
AU - Clauditz, Till S
AU - Steurer, Stefan
AU - Minner, Sarah
AU - Wilczak, Waldemar
AU - Polonski, Adam
N1 - Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Tripartite motif containing 24 (TRIM24) is a multifunctional protein involved in p53 degradation, chromatin binding, and transcriptional modulation of nuclear receptors. Emerging research has revealed that upregulation of TRIM24 in numerous tumor types is linked to poor prognosis, attributing an important role to TRIM24 in tumor biology. In order to better understand the role of TRIM24 in prostate cancer, we analyzed its immunohistochemical expression on a tissue microarray containing >17,000 prostate cancer specimens. TRIM24 immunostaining was detectable in 61% of 15,321 interpretable cancers, including low expression in 46% and high expression in 15% of cases. TRIM24 upregulation was associated with high Gleason grade, advanced pathologic tumor stage, lymph node metastasis, higher preoperative prostate-specific antigen level, increased cell proliferation as well as increased genomic instability, and predicted prognosis independent of clinicopathologic parameters available at the time of the initial biopsy (all P<0.0001). TRIM24 upregulation provides additional prognostic information in prostate cancer, particularly in patients with low Gleason grade tumors who may be eligible for active surveillance strategies, suggesting promising potential for TRIM24 in the routine diagnostic work-up of these patients.
AB - Tripartite motif containing 24 (TRIM24) is a multifunctional protein involved in p53 degradation, chromatin binding, and transcriptional modulation of nuclear receptors. Emerging research has revealed that upregulation of TRIM24 in numerous tumor types is linked to poor prognosis, attributing an important role to TRIM24 in tumor biology. In order to better understand the role of TRIM24 in prostate cancer, we analyzed its immunohistochemical expression on a tissue microarray containing >17,000 prostate cancer specimens. TRIM24 immunostaining was detectable in 61% of 15,321 interpretable cancers, including low expression in 46% and high expression in 15% of cases. TRIM24 upregulation was associated with high Gleason grade, advanced pathologic tumor stage, lymph node metastasis, higher preoperative prostate-specific antigen level, increased cell proliferation as well as increased genomic instability, and predicted prognosis independent of clinicopathologic parameters available at the time of the initial biopsy (all P<0.0001). TRIM24 upregulation provides additional prognostic information in prostate cancer, particularly in patients with low Gleason grade tumors who may be eligible for active surveillance strategies, suggesting promising potential for TRIM24 in the routine diagnostic work-up of these patients.
U2 - 10.1097/PAI.0000000000000901
DO - 10.1097/PAI.0000000000000901
M3 - SCORING: Journal article
C2 - 33491944
VL - 29
SP - e29-e38
JO - APPL IMMUNOHISTO M M
JF - APPL IMMUNOHISTO M M
SN - 1541-2016
IS - 4
ER -